International Registry and Biorepository for TMA(Thrombotic Microangiopathy)

This study is currently recruiting participants.

Verified by North Shore Long Island Jewish Health System, February 2009

First Received: January 2, 2008 Last Updated: February 25, 2009 History of Changes

Sponsors and Collaborators:	North Shore Long Island Jewish Health System Children's Hospital of Philadelphia Mario Negri Institute for Pharmacological Research Mount Sinai School of Medicine University of Virginia Montreal Children's Hospital of the MUHC University of Utah Stollery Children's Hospital National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by:	North Shore Long Island Jewish Health System
ClinicalTrials.gov Identifier:	NCT00593229

Purpose

This registry will collect clinical data and store biosamples (seru, plasma, urine, and DNA) annually from pediatric patients with thrombotic mcroangiopathy

Condition
Thrombotic Microangiopathy Hemolytic Uremic Syndrome Thrombotic Thrombocytopenic Purpura

Genetics Home Reference related topics: factor V Leiden thrombophilia hemophilia prothrombin thrombophilia thrombotic thrombocytopenic purpura

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case-Only, Prospective
Official Title:	An Observational Study of All Forms of Thrombotic Microangiopathy in Pediatric Patients

Further study details as provided by North Shore Long Island Jewish Health System:

Primary Outcome Measures:

Determine epidemiology and outcomes of the various forms of TMA [ Time Frame: Ongoing ] [ Designated as safety issue: No ]
Determine genetic causes of TMA [ Time Frame: Ongoing ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Initiate clinical trials in TMA [ Time Frame: In the future ] [ Designated as safety issue: Yes ]

Biospecimen Retention: Samples With DNA

Biospecimen Description:

Serum, plasma, urine, and DNA

Estimated Enrollment:	60
Study Start Date:	January 2007

Groups/Cohorts
3 Familial atypical HUS
4 Thrombotic thrombocytopenic purpura (TTP)
1 Severe diarrhea-associated hemolytic uremic syndrome (D+HUS)
2 Non-familial atypical HUS

Detailed Description:

Children age, 6 months - 18 years, are eligible if they have one of the following categories of thrombotic microangiopathy (TMA):(1) severe D+HUS; (2) non-familial atypical HUS; (3) familial atypical HUS; or (4) TTP

Patients are seen intially and annually thereafter

Biosamples are collected for storage annually.

Eligibility

Ages Eligible for Study:	6 Months to 18 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

Pediatric patients, 6 months - 18 years

Criteria

Inclusion Criteria:

Severe HUS, familial or non-familial atypical HUS, TTP

Exclusion Criteria:

None

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00593229

Contacts

Contact: Howard Trachtman, MD

718-470-3423

trachtma@lij.edu

Locations

United States, New York
Schneider Chldren's Hospital	Recruiting
New Hyde Park, New York, United States, 11040
Contact: Howard Trachtman, MD 718-470-3423 trachtma@lij.edu
Contact: Cathy Hoffman, RN 718-470-3499 choffman@nshs.edu
Principal Investigator: Howard Trachtman, MD

Sponsors and Collaborators

North Shore Long Island Jewish Health System

Children's Hospital of Philadelphia

Mario Negri Institute for Pharmacological Research

Mount Sinai School of Medicine

University of Virginia

Montreal Children's Hospital of the MUHC

University of Utah

Stollery Children's Hospital

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Investigators

Principal Investigator:

Howard Trachtman, MD

Schneider Children's Hospital

More Information

Additional Information:

Study is listed at Clinical Trials tab This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Feinstein Institute for Medical Research of North Shore-LIJ Health System ( Howard Trachtman )
Study ID Numbers:	DK71221, DK R21-71221
Study First Received:	January 2, 2008
Last Updated:	February 25, 2009
ClinicalTrials.gov Identifier:	NCT00593229 History of Changes
Health Authority:	United States: Federal Government; United States: Institutional Review Board

Keywords provided by North Shore Long Island Jewish Health System:

Thrombotic microangiopathy (TMA)
Hemolytic uremic syndrome (HUS)
Thrombotic thrombocytopenic purpura (TTP)

Study placed in the following topic categories:

Purpura
Azotemia
Hematologic Diseases
Thrombophilia
Blood Coagulation Disorders
Blood Platelet Disorders
Vascular Diseases
Anemia
Anemia, Hemolytic
Thrombotic Thrombocytopenic Purpura, Acquired
Hemostatic Disorders
Purpura, Thrombotic Thrombocytopenic

Hemolytic-Uremic Syndrome
Purpura, Thrombocytopenic
Thrombosis
Thrombocytopathy
Signs and Symptoms
Embolism and Thrombosis
Thrombocytopenia
Urologic Diseases
Embolism
Uremia
Kidney Diseases
Hemolytic-uremic Syndrome

Additional relevant MeSH terms:

Skin Manifestations
Thrombophilia
Purpura, Thrombotic Thrombocytopenic
Purpura, Thrombocytopenic
Hemolytic-Uremic Syndrome
Signs and Symptoms
Thrombocytopenia
Pathologic Processes
Urologic Diseases
Syndrome
Cardiovascular Diseases
Kidney Diseases
Azotemia

Purpura
Disease
Immune System Diseases
Hematologic Diseases
Blood Platelet Disorders
Blood Coagulation Disorders
Anemia
Vascular Diseases
Anemia, Hemolytic
Thrombosis
Embolism and Thrombosis
Uremia

ClinicalTrials.gov processed this record on May 07, 2009